Replies to post #11471 on Pluristem Therapeutics Inc (PSTI)

[Spideyboy]

Ok, let's look at United then.

They were founded in 1996.

And they had their first approval in 2002 for Remodulin (treprostinil), then they just reformulated the same product to make Tyvaso and Orenitram.

So they got their first approval within 8 years of being founded, that sounds too quick. And indeed it is too quick.

United licensed-in treprostinil from GSK in 1997. So yes it was much faster to get them to a higher share price as the drug was already part way through development.

Additionally their other product Adcirca was licensed in by United in 2008, from Eli Lilly when most of the research was done.

And for United final product Unituxin, that was also bought in, as it was already available having been developed by the National Cancer Institute and which was halted early due to clear efficacy and approved by the FDA in 2009. United just came in in 2010 and bought the drug. So United didn't develop anything at all with Unituxin.


So for all of their products they didn't even develop them themselves for a large and time consuming part in not didn't do any development at all. So yes, it would have been much faster to reach a higher share price.

Also TiGenix that just got their approval today (the first allogeneic MSC product ever in the EU), while they were founded before us in 2000, they actually had to buy-in their product via acquiring Spanish Cellerix SL, which had already started the development.

Meanwhile PSTI on the other-hand has been developing their products from scratch in-house, having only bought-in the fundamental technology on which the company is based in 2007.

So given the United and TiGenix bought in or in-licensed products that were already in development or marketed, I'd say if PSTI can get something to market from scratch in a pioneering new field of MSCs and get it done in the entire lifetime of TiGenix (again who bought in the product), and just got the first ever EU MSC allogeneic product approved, then I'd say that's pretty good going from PSTI.

On Bull City, I haven't found much either, but I think his expertise is not going to most valuable in that capacity compared to his experience getting filgrastim to market and for understanding of the processes of getting that anti-ARS (anti-radiation in bone marrow patients) product approved and commercialised.

As for Roger Jeffs appointment today. Stupid Clowns managing to bring on a relevant and experienced guy like this, whatever were those clowns thinking?